Allogene Therapeutics Inc (NAS:ALLO)
$ 2.06 -0.02 (-0.96%) Market Cap: 431.14 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.76 GF Score: 28/100

Allogene Therapeutics Inc to Review The Potential Innovation of Allogeneic CAR T Therapy in Multiple Myeloma Transcript

Dec 05, 2020 / 07:00PM GMT
Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Welcome to the Allogene Therapeutics webinar to discuss initial results from our Phase I UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma presented today at the American Society of Hematology. We're looking forward to discussing data from our second program that highlights progress towards our goal of making AlloCAR T therapy a reality for patients.

Today's call is being webcast on our website and will be available for replay. Before the start of this webinar, I'd like to note that we issued a press release that provides the details of this data. We've also posted the materials that will be presented during the webinar on our website at www.allogene.com under the Investor Relations section. After our formal presentation, I will open up the call for questions.

On the call today will -- are Dr. David Chang and Dr. Rafael Amado. We're also pleased to have Dr. Parameswaran Hari from the Medical College of Wisconsin joining us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot